A Camelid-Derived STAT-Specific Nanobody Inhibits Neuroinflammation and Ameliorates Experimental Autoimmune Encephalomyelitis (EAE)
Cells · 2024
DOI: 10.3390/cells13121042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Evaristus C Mbanefo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Single-Domain Antibodies, Th17 Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Programs of NEI/NIH.
Abstract (Originalsprache)
Proinflammatory T-lymphocytes recruited into the brain and spinal cord mediate multiple sclerosis (MS) and currently there is no cure for MS. IFN-γ-producing Th1 cells induce ascending paralysis in the spinal cord while IL-17-producing Th17 cells mediate cerebellar ataxia. STAT1 and STAT3 are required for Th1 and Th17 development, respectively, and the simultaneous targeting of STAT1 and STAT3 pathways is therefore a potential therapeutic strategy for suppressing disease in the spinal cord and brain. However, the pharmacological targeting of STAT1 and STAT3 presents significant challenges because of their intracellular localization. We have developed a STAT-specific single-domain nanobody (SBT-100) derived from camelids that targets conserved residues in Src homolog 2 (SH2) domains of STAT1 and STAT3. This study investigated whether SBT-100 could suppress experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. We show that SBT-100 ameliorates encephalomyelitis through suppressing the expansion of Th17 and Th1 cells in the brain and spinal cord. Adoptive transfer experiments revealed that lymphocytes from SBT-100-treated EAE mice have reduced capacity to induce EAE, indicating that the immunosuppressive effects derived from the direct suppression of encephalitogenic T-cells. The small size of SBT-100 makes this STAT-specific nanobody a promising immunotherapy for CNS autoimmune diseases, including multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- Singh Biotechnology, 1547 Fox Grape Loop, Lutz, FL 33558, USA.
ORCID-Profile: Evaristus C Mbanefo, Allison Seifert, Manoj Kumar Yadav, Cheng-Rong Yu, Vijayaraj Nagarajan, Ashutosh Parihar
Förderung
- Intramural Research Programs of NEI/NIH
Zitieren
APA
Mbanefo, E. C., Seifert, A., Yadav, M. K., Yu, C. R., Nagarajan, V., Parihar, A., Singh, S., & Egwuagu, C. E. (2024). A Camelid-Derived STAT-Specific Nanobody Inhibits Neuroinflammation and Ameliorates Experimental Autoimmune Encephalomyelitis (EAE). Cells. https://doi.org/10.3390/cells13121042
Vancouver
Mbanefo EC, Seifert A, Yadav MK, Yu CR, Nagarajan V, Parihar A, et al. A Camelid-Derived STAT-Specific Nanobody Inhibits Neuroinflammation and Ameliorates Experimental Autoimmune Encephalomyelitis (EAE). Cells. 2024. doi:10.3390/cells13121042
BibTeX
@article{Mbanefo2024,
author = {Mbanefo, Evaristus C and Seifert, Allison and Yadav, Manoj Kumar and Yu, Cheng-Rong and Nagarajan, Vijayaraj and Parihar, Ashutosh and Singh, Sunanda and Egwuagu, Charles E},
title = {A Camelid-Derived STAT-Specific Nanobody Inhibits Neuroinflammation and Ameliorates Experimental Autoimmune Encephalomyelitis (EAE)},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13121042}
}
EUVIMED